RBC Capital analyst Kennen MacKay weighed in on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) after the company announced the positive ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE